Literature DB >> 28864833

Impact of multiple malignancies on surgical outcomes in patients with 1 cm or smaller non-small cell lung cancer.

Takuma Tsukioka1, Nobuhiro Izumi2, Shinjiro Mizuguchi2, Chung Kyukwang2, Hiroaki Komatsu2, Michihito Toda2, Kantaro Hara2, Hikaru Miyamoto2, Noritoshi Nishiyama2.   

Abstract

BACKGROUND: Because most patients with small-sized non-small cell lung cancer (NSCLC) are asymptomatic, their lesions are detected by cancer screenings or routine checkups for other diseases. Incidences of multiple malignancies have been reported to be 27% in patients with stage I-III NSCLC. Some patients have treatment histories for other malignancies, and their small-sized NSCLC was incidentally detected during follow-up. There is no established report regarding the influence of multiple malignancies on small-sized NSCLC prognosis. Therefore, we investigated the correlation between multiple malignancies and surgical outcomes in patients with small-sized NSCLC.
METHODS: In total, 44 patients underwent definitive pulmonary resection for NSCLC of 1 cm or smaller between January 2003 and December 2012. Tumor size was measured by macroscopic findings of the resected specimens, and we then retrospectively investigated their clinical courses.
RESULTS: One patient had hemoptysis symptoms, whereas 43 patients were asymptomatic; among them, NSCLC was detected by examinations for other diseases in 31 patients and by cancer screening in 12 patients. In total, 20 patients (45%) had multiple malignancies. The median follow-up period was 68 months. One patient had a recurrence from current NSCLC. No patients died of current NSCLC. The overall 5-year survival rate was 90% for all patients. Patients with multiple malignancies had significantly poorer prognoses compared with those without multiple malignancies (P = 0.016). However, patients with treatment intervals of more than 5 years had prognoses equivalent to those of patients without multiple malignancies (P = 0.829). Only the presence of multiple malignancies was a significantly poor prognostic factor in univariate and multivariate analyses.
CONCLUSION: NSCLC of 1 cm or smaller showed good prognoses. The presence of multiple malignancies was a significantly poor prognostic factor, and short treatment intervals also correlated with poor prognosis.

Entities:  

Keywords:  Multiple malignancies; Non-small cell lung cancer; Prognostic factor; Treatment interval

Mesh:

Year:  2017        PMID: 28864833     DOI: 10.1007/s10147-017-1185-z

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  15 in total

1.  Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B.

Authors:  O Kaufmann; M Dietel
Journal:  Histopathology       Date:  2000-01       Impact factor: 5.087

2.  Different histological subtypes of peripheral lung cancer based on emphysema distribution in patients with both airflow limitation and CT-determined emphysema.

Authors:  Beomsu Shin; Sumin Shin; Myung Jin Chung; Hyun Lee; Won-Jung Koh; Hojoong Kim; Hye Yun Park
Journal:  Lung Cancer       Date:  2016-12-20       Impact factor: 5.705

3.  Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer<=1 cm in size: a review of SEER data.

Authors:  Max Kates; Scott Swanson; Juan P Wisnivesky
Journal:  Chest       Date:  2010-06-24       Impact factor: 9.410

4.  Long-term survival and recurrence in patients with resected non-small cell lung cancer 1 cm or less in size.

Authors:  Paul C Lee; Robert J Korst; Jeffrey L Port; Yaniv Kerem; Amanda L Kansler; Nasser K Altorki
Journal:  J Thorac Cardiovasc Surg       Date:  2006-10-30       Impact factor: 5.209

5.  Clinical characteristics and advantages of primary peripheral micro-sized lung adenocarcinoma over small-sized lung adenocarcinoma.

Authors:  Wang-Yu Zhu; Lin-Lin Tan; Zhao-Yu Wang; Shan-Jun Wang; Li-Yun Xu; Wei Yu; Zhi-Jun Chen; Yong-Kui Zhang
Journal:  Eur J Cardiothorac Surg       Date:  2015-09-15       Impact factor: 4.191

6.  Cytokeratin expression profiling is useful for distinguishing between primary squamous cell carcinoma of the lung and pulmonary metastases from tongue cancer.

Authors:  Takehiko Ohba; Noriko Motoi; Yukinori Kimura; Sakae Okumura; Kazuyoshi Kawabata; Yasuyuki Yoshizawa; Naohiko Inase; Yuichi Ishikawa
Journal:  Pathol Int       Date:  2010-08       Impact factor: 2.534

7.  The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.

Authors:  Ramón Rami-Porta; Vanessa Bolejack; John Crowley; David Ball; Jhingook Kim; Gustavo Lyons; Thomas Rice; Kenji Suzuki; Charles F Thomas; William D Travis; Yi-Long Wu
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609

Review 8.  Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients?

Authors:  Guy Shakhar; Shamgar Ben-Eliyahu
Journal:  Ann Surg Oncol       Date:  2003-10       Impact factor: 5.344

9.  Initial medical attention on patients with early-stage non-small cell lung cancer.

Authors:  Xing Chen; Ivan P Gorlov; Jun Ying; Kelly W Merriman; Marek Kimmel; Charles Lu; Cielito C Reyes-Gibby; Olga Y Gorlova
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

10.  Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors.

Authors:  Meng Lv; Xiao Zhang; Yanwei Shen; Fan Wang; Jiao Yang; Biyuan Wang; Zheling Chen; Pan Li; Xiaoman Zhang; Shuting Li; Jin Yang
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

View more
  1 in total

1.  The clinical value of 18F-fluoroestradiol in assisting individualized treatment decision in dual primary malignancies.

Authors:  Ziyi Yang; Yizhao Xie; Cheng Liu; Xin Liu; Shaoli Song; Yingjian Zhang; Rui Ge; Biyun Wang; Zhongyi Yang
Journal:  Quant Imaging Med Surg       Date:  2021-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.